DOP2013000213A - Compuestos de complejos de fe(iii) para el tratamiento y profilaxis de sintomas de deficiencia de hierro y anemias por deficiencia de hierro - Google Patents

Compuestos de complejos de fe(iii) para el tratamiento y profilaxis de sintomas de deficiencia de hierro y anemias por deficiencia de hierro

Info

Publication number
DOP2013000213A
DOP2013000213A DO2013000213A DO2013000213A DOP2013000213A DO P2013000213 A DOP2013000213 A DO P2013000213A DO 2013000213 A DO2013000213 A DO 2013000213A DO 2013000213 A DO2013000213 A DO 2013000213A DO P2013000213 A DOP2013000213 A DO P2013000213A
Authority
DO
Dominican Republic
Prior art keywords
iron deficiency
compounds
treatment
complexes
profilaxis
Prior art date
Application number
DO2013000213A
Other languages
English (en)
Inventor
Franz Durrenberger
Peter Otto Geisser
Wilm Buhr
Felix Funk
Thomas Bark
Susanna Burckhardt
Michael Burgert
Camillo Canclini
Aris Kalogerakis
Simona Mayer
Erik Philipp
Stefan Reim
Diana Sieber
Jorg Schmitt
Katrin Schwarz
Original Assignee
Vifor Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44140927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2013000213(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor Int Ag filed Critical Vifor Int Ag
Publication of DOP2013000213A publication Critical patent/DOP2013000213A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a compuestos de complejos de hierro(lll) y composiciones farmacéuticas que comprenden los mismos para su uso como medicamentos, en particular para el tratamiento y/o profilaxis de síntomas de deficiencia de hierro y anemias por deficiencia de hierro.
DO2013000213A 2011-03-29 2013-09-26 Compuestos de complejos de fe(iii) para el tratamiento y profilaxis de sintomas de deficiencia de hierro y anemias por deficiencia de hierro DOP2013000213A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11160151 2011-03-29

Publications (1)

Publication Number Publication Date
DOP2013000213A true DOP2013000213A (es) 2013-11-15

Family

ID=44140927

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000213A DOP2013000213A (es) 2011-03-29 2013-09-26 Compuestos de complejos de fe(iii) para el tratamiento y profilaxis de sintomas de deficiencia de hierro y anemias por deficiencia de hierro

Country Status (32)

Country Link
US (1) US9422247B2 (es)
EP (1) EP2691376B1 (es)
JP (1) JP5923161B2 (es)
KR (1) KR101889050B1 (es)
CN (1) CN103429575B (es)
AR (1) AR085736A1 (es)
AU (1) AU2012234292B2 (es)
BR (1) BR112013024722B1 (es)
CA (1) CA2829240C (es)
CL (1) CL2013002766A1 (es)
CO (1) CO6811850A2 (es)
CR (1) CR20130485A (es)
DK (1) DK2691376T3 (es)
DO (1) DOP2013000213A (es)
EA (1) EA026192B1 (es)
EC (1) ECSP13012904A (es)
ES (1) ES2560964T3 (es)
GT (1) GT201300224A (es)
HU (1) HUE026712T2 (es)
IL (1) IL228502A (es)
MA (1) MA34977B1 (es)
MX (1) MX358194B (es)
MY (1) MY168952A (es)
PE (1) PE20141319A1 (es)
PH (1) PH12013501968A1 (es)
PL (1) PL2691376T3 (es)
PT (1) PT2691376E (es)
SG (1) SG193981A1 (es)
TN (1) TN2013000379A1 (es)
TW (1) TWI510496B (es)
WO (1) WO2012130882A1 (es)
ZA (1) ZA201308050B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105246473B (zh) 2012-12-21 2018-07-13 维福（国际）股份有限公司 用于缺铁症状和缺铁性贫血的治疗和预防的Fe(III)络合化合物
CN103951552B (zh) * 2014-04-11 2015-09-30 浙江宏元药业有限公司 瑞舒伐他汀中间体及其制备方法
RU2625739C1 (ru) * 2016-09-28 2017-07-18 Общество с ограниченной ответственностью Научно-производственное предприятие "Эксорб" Фармакологическая композиция на основе соединений железа

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US474670A (en) 1892-05-10 Automatic fire-alarm
GB842637A (en) 1955-12-27 1960-07-27 Andre Georges Jules Jallais Glass frames, more especially for forced cultivation
EP0107458B1 (en) 1982-10-22 1987-07-29 National Research Development Corporation Pharmaceutical compositions
GB8325496D0 (en) * 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
US4788281A (en) 1984-01-04 1988-11-29 Tosoni Anthony L Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof
GB8410289D0 (en) 1984-04-19 1984-05-31 Callingham B A Pharmaceutical compositions
IT1222654B (it) 1987-09-14 1990-09-12 Schering Ag Complesso micellare di ferro-citrato
JPH0283400A (ja) 1988-09-21 1990-03-23 Snow Brand Milk Prod Co Ltd 鉄カゼインの製造方法
ES2044777B1 (es) 1992-03-03 1994-08-01 Dabeer Sa Procedimiento de obtencion de un quelato de hierro de gran solubilidad.
US20030236224A1 (en) 1997-12-09 2003-12-25 Hedlund Bo E. Modified polysaccharides exhibiting altered biological recognition
IT1297022B1 (it) 1997-12-24 1999-08-03 Chemi Spa Complesso di ferro-succinilcaseina, processo per la sua preparazione e composizioni farmaceutiche che lo contengono
DE10253843B3 (de) 2002-11-14 2004-05-06 Bizerba Gmbh & Co. Kg Etikettiervorrichtung für bewegte Gegenstände und Verfahren zur Etikettierung von bewegten Gegenständen
JP4931352B2 (ja) * 2004-01-14 2012-05-16 月桂冠株式会社 鉄補給剤及びその利用
ZA200702421B (en) 2004-10-08 2008-09-25 Unilever Plc Iron complex for use in the treatment and/or prevention of nutritional disorders
US20090035385A1 (en) 2004-12-22 2009-02-05 Drugtech Corporation Compositions including iron
CN100443485C (zh) 2005-04-08 2008-12-17 吴华君 叶绿酸合铁钠盐衍生物、制备方法及用途
JP4948056B2 (ja) * 2005-09-02 2012-06-06 月桂冠株式会社 疲労の予防又は改善剤
WO2007062546A1 (fr) 2005-11-30 2007-06-07 Chongqing Pharmaceutical Research Institute Co., Ltd. Complexes fer-saccharide faciles a reconstituer et leur procede de fabrication
FR2916592B1 (fr) 2007-05-25 2017-04-14 Groupe Des Ecoles De Telecommunications(Get)-Ecole Nat Superieure Des Telecommunications(Enst) Procede de securisation d'echange d'information,dispositif, et produit programme d'ordinateur correspondant
CN101481404B (zh) 2008-12-17 2011-10-05 中国农业大学 一种酶解乳蛋白亚铁络合物微胶囊补铁剂及其制备方法

Also Published As

Publication number Publication date
KR20140027196A (ko) 2014-03-06
BR112013024722B1 (pt) 2022-04-12
SG193981A1 (en) 2013-11-29
IL228502A (en) 2015-02-26
ECSP13012904A (es) 2013-12-31
EA026192B1 (ru) 2017-03-31
EP2691376B1 (de) 2015-12-09
PL2691376T3 (pl) 2016-06-30
BR112013024722A2 (pt) 2016-12-20
KR101889050B1 (ko) 2018-08-20
ES2560964T3 (es) 2016-02-23
PT2691376E (pt) 2016-03-02
US9422247B2 (en) 2016-08-23
CA2829240A1 (en) 2012-10-04
TWI510496B (zh) 2015-12-01
AU2012234292A1 (en) 2013-10-17
WO2012130882A1 (de) 2012-10-04
ZA201308050B (en) 2016-01-27
CN103429575A (zh) 2013-12-04
CO6811850A2 (es) 2013-12-16
MX358194B (es) 2018-07-16
US20140162994A1 (en) 2014-06-12
HUE026712T2 (en) 2016-07-28
IL228502A0 (en) 2013-12-31
PH12013501968A1 (en) 2013-12-16
MY168952A (en) 2019-01-28
JP2014509624A (ja) 2014-04-21
CN103429575B (zh) 2016-08-31
JP5923161B2 (ja) 2016-05-24
TW201245212A (en) 2012-11-16
MX2013010964A (es) 2013-10-17
EA201301083A1 (ru) 2014-03-31
CA2829240C (en) 2016-11-22
NZ616045A (en) 2015-04-24
GT201300224A (es) 2015-01-20
PE20141319A1 (es) 2014-10-29
TN2013000379A1 (en) 2015-01-20
AR085736A1 (es) 2013-10-23
CL2013002766A1 (es) 2014-03-21
AU2012234292B2 (en) 2016-09-22
MA34977B1 (fr) 2014-03-01
EP2691376A1 (de) 2014-02-05
DK2691376T3 (en) 2016-02-15
CR20130485A (es) 2014-05-20

Similar Documents

Publication Publication Date Title
CR20120478A (es) COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
NI201400032A (es) Piridopirazinas anticancerígenas via la
CR20150326A (es) Inhibidores de autotaxina
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MY173843A (en) Amidine substituted ?-lactam compounds, their preparation and use as antibacterial agents
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
GT201400111A (es) Triazolopiridinas sustituidas
MY173521A (en) Trpv4 antagonists
DOP2014000012A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
BR112013018290A2 (pt) antagonistas de receptor 2 ativado por protease (par2)
TR201903918T4 (tr) Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
CO6321288A2 (es) Sales de compuestos inhibidores de vih
BR112015023878A2 (pt) composto, composição farmacêutica, e, uso de um composto
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
DOP2013000213A (es) Compuestos de complejos de fe(iii) para el tratamiento y profilaxis de sintomas de deficiencia de hierro y anemias por deficiencia de hierro
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
EA201401045A1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
AR086606A1 (es) Compuestos del complejo de fe(iii) para el tratamiento y profilaxis de los sintomas de la deficiencia de hierro y las anemias por deficiencia de hierro
BR112015024571A2 (pt) compostos de complexo de ferro(iii), medicamento, e, composição
MX2015007974A (es) Compuestos de complejos de fe (iii) para el tratamiento y la profilaxis de los sintomas de la deficiencia de hierro y las anemias por deficiencia de hierro.
NI201200162A (es) Inhibidores de pirazolil quinoxalina cinasa